Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Multicenter, Prospective, Open-Label Study Describing the Efficacy and Safety of Belimumab Administered Subcutaneously in Adult Participants With Early Systemic Lupus Erythematosus

NCT06411249 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT06411249
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06411249 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Multicenter, Prospective, Open-Label Study Describing the Efficacy and Safety of Belimumab Administered Subcutaneously in Adult Participants With Early Systemic Lupus Erythematosus
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Active, not recruiting
Start date
June 6, 2024
Completion date
July 17, 2029
Enrollment
303 (actual)
Sites
109

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus